Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222592 · ClinicalTrials.gov registry record · NA

MOBoxy: MoblO2 to Maintain Oxygenation

A NA study, sponsored by National Jewish Health.

Not yet
Registry status
NA
Development phase
48
Enrollment target

NCT07222592 is a NA study that has not yet begun recruiting, run by National Jewish Health. The registered enrollment target is 48 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222592, a NA study, has not yet begun recruiting, sponsored by National Jewish Health.

NOT YET RECRUITING
Registry status
NA
Development phase
48 participants
Enrollment target

Study Summary

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and int

Interventions

  • DEVICE MoblO2 control

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2025-12
Est. Completion 2026-08
Phase NA

Sponsor

National Jewish Health

83 total trials

What the Registry Record Tells You About NCT07222592

The ClinicalTrials.gov registry entry for NCT07222592 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MoblO2 control is the first listed.

NCT07222592 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07222592 about?

NCT07222592 is a clinical study titled "MOBoxy: MoblO2 to Maintain Oxygenation". Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) t...

What is the current status of trial NCT07222592?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2025-12. Estimated completion is 2026-08.

What interventions are being tested in trial NCT07222592?

The interventions under investigation include: MoblO2 control (DEVICE).

Who is sponsoring clinical trial NCT07222592?

This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.